Document Detail


Conivaptan (Yamanouchi).
MedLine Citation:
PMID:  12054079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Yamanouchi is developing conivaptan, an orally active vasopressin V1A and V2 antagonist for the potential treatment of heart failure, edema and hyponatremia. The company anticipated launch of the product for hyponatremia in 2002 [362201]. By May 2001, Yamanouchi was continuing phase II trials in Japan for hyponatremia and heart failure, and in the US and Europe for heart failure, and phase III trials in the US and Europe for hyponatremia [411763]. In July 2000, it had been reported that conivaptan was undergoing phase III trials in both the US and Europefor hyponatremia and heart failure [377561]. In April 1998, Warner-Lambert (now Pfizer) acquired the rights to YM-087 for US, South America, Europe and Africa, while Yamanouchi retains copromotion rights, but by November 2000, Pfizer had cancelled its licensing contract to market the drug in the US [397901]. In September 2001, analysts at Morgan Stanley predicted launch of conivaptan for hyponatremia in the US between 2004 and 2005 [422782]. In October 2001, analysts at Credit Suisse First Boston predicted that an NDA would be filed in 2002 followed by launch in 2003, with peak annual sales of $50 million and $300 million for hyponatremia and heart failure, respectively [427028].
Authors:
Alberto Martinez-Castelao
Related Documents :
23438549 - Mitral annulus reconstruction and giant left atrial reduction plasty.
15476569 - Constrictive pericarditis versus restrictive cardiomyopathy: challenges in diagnosis an...
17568159 - Severe transient cardiac failure caused by placental chorangiosis.
17560599 - Decreased phosphorylation levels of cardiac myosin-binding protein-c in human and exper...
11163739 - Diagnosis of heart failure in elderly patients in primary care.
18158479 - Pathophysiology of right ventricular failure.
11954679 - Appropriateness of coronary revascularization for patients with chronic stable angina o...
3799439 - Prevalence of late potentials in patients undergoing holter monitoring.
24405559 - Left ventricular systolic dysfunction detected by speckle tracking in hypertensive pati...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  3     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-06-10     Completed Date:  2002-12-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  89-95     Citation Subset:  IM    
Affiliation:
Hospital Bellvitge CSUB, University of Barcelona, Spain. 9349amc@webcmb.comb.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzazepines / chemistry,  pharmacology,  therapeutic use*
Clinical Trials as Topic / methods,  statistics & numerical data
Edema / drug therapy
Heart Failure / drug therapy
Humans
Hyponatremia / drug therapy
Technology, Pharmaceutical / methods,  statistics & numerical data
Chemical
Reg. No./Substance:
0/Benzazepines; 0/conivaptan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiarrhythmics in atrial fibrillation.
Next Document:  CVT-510 (CV Therapeutics).